517 related articles for article (PubMed ID: 32502841)
1. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE
Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381
[TBL] [Abstract][Full Text] [Related]
3. Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo.
Su CM; Weng YS; Kuan LY; Chen JH; Hsu FT
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429376
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
[TBL] [Abstract][Full Text] [Related]
5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
6. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
7. Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.
Chiang CH; Chung JG; Hsu FT
Environ Toxicol; 2019 Jun; 34(6):679-688. PubMed ID: 30801954
[TBL] [Abstract][Full Text] [Related]
8. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Chen D; Wei L; Yu J; Zhang L
Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
Tsai JJ; Pan PJ; Hsu FT
Oncol Rep; 2017 Feb; 37(2):1036-1044. PubMed ID: 28000898
[TBL] [Abstract][Full Text] [Related]
14. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
[TBL] [Abstract][Full Text] [Related]
15. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
Morgillo F; Martinelli E; Troiani T; Orditura M; De Vita F; Ciardiello F
PLoS One; 2011; 6(12):e28841. PubMed ID: 22174910
[TBL] [Abstract][Full Text] [Related]
17. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
18. SHP-1 is a target of regorafenib in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF
Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018
[TBL] [Abstract][Full Text] [Related]
19. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
